NCT05889767

Brief Summary

Exercise acutely increases gut permeability and inflammation, even in healthy populations. However, whether this response differs in groups at-risk for CVD that present with low-grade inflammation (e.g., normal-weight obesity) has yet to be examined. The investigators aim to measure serum indicators of gut permeability in those with normal-weight obesity pre- and post-short, intense exercise and sustained, moderate exercise

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jan 2023

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 10, 2023

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

May 4, 2023

Completed
1 month until next milestone

First Posted

Study publicly available on registry

June 5, 2023

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2023

Completed
Last Updated

June 5, 2023

Status Verified

June 1, 2023

Enrollment Period

7 months

First QC Date

May 4, 2023

Last Update Submit

June 2, 2023

Conditions

Outcome Measures

Primary Outcomes (5)

  • Serum concentrations of FABP2 following short, intense exercise

    The investigators will examine peak and absolute change in this indicator of gut permeability after the VO2 max test on a cycle ergometer.

    Approximately 8 months

  • Serum concentrations of LBP following short, intense exercise

    The investigators will examine peak and absolute change in this indicator of gut permeability after the VO2 max test on a cycle ergometer.

    Approximately 8 months

  • Serum concentrations of sCD14 following short, intense exercise

    The investigators will examine peak and absolute change in this indicator of gut permeability after the VO2 max test on a cycle ergometer.

    Approximately 8 months

  • Serum concentrations of FABP2 following sustained, moderate exercise

    The investigators will examine peak and absolute change in this indicator of gut permeability after 45-minutes of exercise at 65% VO2 max on a cycle ergometer.

    Approximately 8 months

  • Serum concentrations of IL-6 following sustained, moderate exercise

    The investigators will examine peak and absolute change in this inflammatory marker after 45-minutes of exercise at 65% VO2 max on a cycle ergometer.

    Approximately 8 months

Secondary Outcomes (4)

  • VO2 Max

    Approximately 8 months

  • Respiratory exchange ratio (RER) during VO2 max test

    Approximately 8 months

  • Maximum workload during exercise sessions

    Approximately 8 months

  • Heart rate dynamics during exercise sessions

    Approximately 8 months

Other Outcomes (6)

  • Body fat percent assessment with dual-energy X-ray absorptiometry (DXA).

    Approximately 8 months

  • Absolute body fat assessment with dual-energy X-ray absorptiometry (DXA)

    Approximately 8 months

  • Lean mass percent assessment with dual-energy X-ray absorptiometry (DXA)

    Approximately 8 months

  • +3 more other outcomes

Study Arms (3)

Normal weight and low body fat percent

ACTIVE COMPARATOR

The low risk comparator group for this study will consist of individuals with normal BMI (18.5 - 24.9 kg/m2) and body fat percent \< 25% (male) or \< 35% (female).

Other: Exercise tests (VO2 max test and 45-minute exercise session at 65% VO2 max)

Normal-weight obesity

EXPERIMENTAL

Individuals with normal-weight obesity will be defined as having normal BMI (18.5 - 24.9 kg/m2), body fat percent \> 25% (male) or \> 35% (female).

Other: Exercise tests (VO2 max test and 45-minute exercise session at 65% VO2 max)

Overt obesity and high body fat percent

ACTIVE COMPARATOR

Overt obesity (BMI \> 30 kg/m2) with high body fat percent (\> 25% \[male\] or \> 35% \[female\]) will be used as a high-risk comparator group.

Other: Exercise tests (VO2 max test and 45-minute exercise session at 65% VO2 max)

Interventions

All participants will complete two exercise sessions: 1. VO2 max test on a cycle ergometer 2. Moderate exercise session (45 minutes at 65% measured VO2 max)

Normal weight and low body fat percentNormal-weight obesityOvert obesity and high body fat percent

Eligibility Criteria

Age18 Years - 50 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Control group: normal BMI, body fat percentage \< 25% (male) or \< 35% (female)
  • Normal-weight obesity: normal BMI, body fat percentage \> 25% (male) or \> 35% (female)
  • Overt obesity: BMI in obesity range, body fat percentage \> 25% (male) or \> 35% (female)

You may not qualify if:

  • Presence of pacemaker
  • Pregnant
  • Postmenopausal status
  • History of chronically using of tobacco products, illicit drugs, anti-inflammatory drugs (e.g., NSAIDs), lipid lowering drugs
  • Recent use of antibiotics (\< 6 weeks) and NSAIDs (\< 3 days)
  • Established cardiometabolic disease (e.g., cardiovascular disease, type 2 diabetes) diseases inflammatory in nature (e.g., rheumatoid arthritis, inflammatory bowel disease), and/or diagnosed irritable bowel syndrome.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

208 Nancy Randolph Davis, Oklahoma State University

Stillwater, Oklahoma, 74078, United States

RECRUITING

MeSH Terms

Conditions

Obesity

Interventions

Exercise Test

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Heart Function TestsDiagnostic Techniques, CardiovascularDiagnostic Techniques and ProceduresDiagnosisRespiratory Function TestsDiagnostic Techniques, Respiratory SystemErgometryInvestigative Techniques

Central Study Contacts

Bryant H Keirns, MS

CONTACT

Sam R Emerson, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: Three study groups (n=10/ group): 1. Normal weight and low body fat percent (BMI 18.5-24.9 kg/m2, body fat percent \< 25% in males or \< 35% in females), 2. Normal-weight obesity (BMI 18.5-24.9 kg/m2, body fat percent \> 25% in males or \> 35% in female) 3. Overt obesity and high body fat percent (BMI \> 30 kg/m2, body fat percent \> 25% in males or \> 35% in females)
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor of Nutritional Sciences

Study Record Dates

First Submitted

May 4, 2023

First Posted

June 5, 2023

Study Start

January 10, 2023

Primary Completion

August 1, 2023

Study Completion

August 1, 2023

Last Updated

June 5, 2023

Record last verified: 2023-06

Locations